Apotex Pty Ltd v AstraZeneca AB (No 2) [2012] FCA 142

Apotex Pty Ltd v AstraZeneca AB (No 2) [2012] FCA 142

Apotex was permitted to pursue its application, but the additional evidence was not sufficient to justify a conclusion different from that reached by Rares J on prima facie infringement or balance of convenience. Claim 1 of the Cation Salt Patent arguably covered Apotex products containing ferric oxide or titanium dioxide, Apotex had not demonstrated a sufficiently strong invalidity case, and the asserted first mover advantage did not outweigh Astra's evidence of serious and irreversible harm from generic entry. Because related proceedings against other generic suppliers were listed for directions on interlocutory relief, the motion was adjourned to be treated as a fresh application based...

Jurisdiction
Australia
Judgment Date
28 February 2012
Procedural Posture
Patent Infringement Proceeding Concerning Generic Rosuvastatin / Amended Interlocutory Application by Apotex to Vary an Interlocutory Injunction
Outcome
Apotex's motion to vary the interlocutory injunction was not acceded to at this stage and was adjourned to 1 March 2012.
Legal Topics
['prima Facie Infringement' 'patent Validity' 'construction of Patent Claims' 'fair Basis' 'utility' 'balance of Convenience' 'variation of Interlocutory Orders' 'abuse of Process']
['patents' 'civil Procedure' 'interlocutory Injunctions'] ['prima Facie Infringement' 'patent Validity' 'construction of Patent Claims' 'fair Basis' 'utility' 'balance of Convenience' 'variation of Interlocutory Orders' 'abuse of Process']

Case Brief

Summary, issues, holding and outcome

More case intelligence is available

Unlock the full research layer for this judgment.

Full judgment text Downloadable case file Legal principles 1 Authorities cited 2 Party arguments 2 Amounts and remedies 1
Sign in to unlock

Procedural Posture

Patent Infringement Proceeding Concerning Generic Rosuvastatin / Amended Interlocutory Application by Apotex to Vary an Interlocutory Injunction

Legal Issues

  1. 1 ['Whether Apotex should be permitted to pursue its application to vary the interlocutory injunction granted on 14 December 2011.' 'Whether the additional evidence displaced the earlier finding of a prima facie case of infringement of the Cation Salt Patent.' 'Whether Apotex had shown a strong case that relevant claims of the Cation Salt Patent were invalid for lack of novelty, lack of fair basis or lack of utility.' 'Whether the balance of convenience favoured varying the injunction to permit Apotex to market 20mg and 40mg rosuvastatin products.']

Ratio Decidendi

Apotex was permitted to pursue its application, but the additional evidence was not sufficient to justify a conclusion different from that reached by Rares J on prima facie infringement or balance of convenience. Claim 1 of the Cation Salt Patent arguably covered Apotex products containing ferric oxide or titanium dioxide, Apotex had not demonstrated a sufficiently strong invalidity case, and the asserted first mover advantage did not outweigh Astra's evidence of serious and irreversible harm from generic entry. Because related proceedings against other generic suppliers were listed for directions on interlocutory relief, the motion was adjourned to be treated as a fresh application based...

Court Disposition

Apotex's motion to vary the interlocutory injunction was not acceded to at this stage and was adjourned to 1 March 2012.

Orders

  • ["The applicant's motion be adjourned to 10.15am on Thursday, 1 March 2012."]